TY - JOUR
T1 - Nociceptors protect sickle cell disease mice from vaso-occlusive episodes and chronic organ damage
AU - Xu, Chunliang
AU - Gulinello, Maria
AU - Frenette, Paul S.
N1 - Funding Information:
Disclosures: P.S. Frenette reported grants from the National Institutes of Health during the conduct of the study; personal fees from Pfizer, grants from Ironwood Pharmaceuticals, and "other" from Cygnal Therapeutics outside the submitted work. He has served as consultant for Pfizer, received research funding from Ironwood Pharmaceuticals, and owns shares of Cygnal Therapeutics. No other disclosures were reported.
Funding Information:
We thank Colette Prophete, George Amatuni, Xizhe Wang, and Peng Guo for technical assistance and members of the Frenette laboratory for helpful discussions, in particular Dr. Xin Gaofor helpful advice. We thank Dr. Kathleen M. Caron (University of North Carolina, Chapel Hill, NC) for providing Ramp1-/-mice. This work was supported by National Institutes of Health R0 grants (HL069438, DK056638, DK116312, and DK112976 to P.S. Frenette). The Biomarker Analytic Research Core is supported by an Institute for Clinical and Translational Research Einstein- Montefiore Clinical and Translational Science Award grant (5UL1TR002556) and an Einstein-Mount Sinai Diabetes Research Center grant (P30-DK020541). The Analytical Imaging Facility was supported by a National Institutes of Health Shared Instrumentation Grant (1S10OD019961). The Rodent Behavior Core was supported by a Rose F. Kennedy Intellectual and Developmental Disabilities Research Center grant (P30 HD071593). Author contributions: C. Xu conceived and designed the research, performed experiments, collected and analyzed data, and wrote the manuscript. M. Gulinello performed the Hargreaves test. P.S. Frenette designed and supervised the research and wrote the manuscript. Disclosures: P.S. Frenette reported grants from the National Institutes of Health during the conduct of the study; personal fees from Pfizer, grants from Ironwood Pharmaceuticals, and "other" from Cygnal Therapeutics outside the submitted work. He has served as consultant for Pfizer, received research funding from Ironwood Pharmaceuticals, and owns shares of Cygnal Therapeutics. No other disclosures were reported.
Funding Information:
This work was supported by National Institutes of Health R0 grants (HL069438, DK056638, DK116312, and DK112976 to P.S. Frenette). The Biomarker Analytic Research Core is supported by an Institute for Clinical and Translational Research Einstein-Montefiore Clinical and Translational Science Award grant (5UL1TR002556) and an Einstein–Mount Sinai Diabetes Research Center grant (P30-DK020541). The Analytical Imaging Facility was supported by a National Institutes of Health Shared Instrumentation Grant (1S10OD019961). The Rodent Behavior Core was supported by a Rose F. Kennedy Intellectual and Developmental Disabilities Research Center grant (P30 HD071593).
Publisher Copyright:
© 2020 Xu et al.
PY - 2021/1/4
Y1 - 2021/1/4
N2 - Sickle cell disease (SCD) is a common hereditary hematologic disorder. SCD patients suffer from acute vaso-occlusive episodes (VOEs), chronic organ damage, and premature death, with few therapeutic options. Although severe pain is a major clinical manifestation of SCD, it remains unknown whether nociception plays a role in SCD pathogenesis. To address this question, we generated nociceptor-deficient SCD mice and found, unexpectedly, that the absence of nociception led to more severe and more lethal VOE, indicating that somatosensory nerves protect SCD mice from VOE. Mechanistically, the beneficial effects of sensory nerves were induced by the neuropeptide calcitonin gene-related peptide (CGRP), which acted on hematopoietic cells. Additionally, oral capsaicin consumption, which can activate somatosensory nerves by binding to TRPV1, dramatically alleviated acute VOE and significantly prevented chronic liver and kidney damage in SCD mice. Thus, the manipulation of nociception may provide a promising approach to treat SCD.
AB - Sickle cell disease (SCD) is a common hereditary hematologic disorder. SCD patients suffer from acute vaso-occlusive episodes (VOEs), chronic organ damage, and premature death, with few therapeutic options. Although severe pain is a major clinical manifestation of SCD, it remains unknown whether nociception plays a role in SCD pathogenesis. To address this question, we generated nociceptor-deficient SCD mice and found, unexpectedly, that the absence of nociception led to more severe and more lethal VOE, indicating that somatosensory nerves protect SCD mice from VOE. Mechanistically, the beneficial effects of sensory nerves were induced by the neuropeptide calcitonin gene-related peptide (CGRP), which acted on hematopoietic cells. Additionally, oral capsaicin consumption, which can activate somatosensory nerves by binding to TRPV1, dramatically alleviated acute VOE and significantly prevented chronic liver and kidney damage in SCD mice. Thus, the manipulation of nociception may provide a promising approach to treat SCD.
UR - http://www.scopus.com/inward/record.url?scp=85092886549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092886549&partnerID=8YFLogxK
U2 - 10.1084/JEM.20200065
DO - 10.1084/JEM.20200065
M3 - Article
C2 - 33045060
AN - SCOPUS:85092886549
SN - 0022-1007
VL - 218
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 1
ER -